Clinical trial
PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry
Recruiting now · Not applicable · 1 countries · Registry ID NCT07598981
Recruiting nowNot applicableObservational
What this study is about
The design is an open-ended prospective observational (non-interventional) registry for subjects living with excess weight or obesity under the care of a qualified provider with documented experience treating patients with obesity
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersAccepted
ConditionObesity
Full registry criteria
Inclusion Criteria: To be eligible to participate in this registry, an individual must meet all of the following criteria: 1. In the opinion of the investigator, the subject is considered a suitable candidate for treatment with a commercially available systemic obesity medication (see Enrollment Eligible Treatments). While subjects do not need to start an obesity medication at the time of registry enrollment, those prescribed a GLP-based or non-GLP-based obesity medication must be initiating the medication for the first time. 2. Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable laws of the jurisdiction in which the research is being conducted at the time of enrollment. 3. Is willing and able to consent to participation in the registry. 4. Is willing and able to complete registry-related forms electronically via personal devices 5. Is willing and able to provide first name, last name, email address, language, and primary time zone for electronic data collection account creation. 6. For US subjects only, is willing and able to provide Personally Identifiable Information which includes full legal name, sex at birth, date of birth, and home address zip code. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in the registry: 1. Has Type 2 diabetes (T2D). 2. Is participating or planning to participate in a blinded clinical trial.
Treatments and study arms
Biospecimen collection
Other
Blood Samples will be collected from subjects. This is optional for the participating subjects
Primary outcomes
Obesity Epidemiology and presentationEvery 6 months for 10 years
The major clinical outcome include an assessment of the epidemiology of Obesity. This will be determined using PROs and ClinROs which will be included as part of the case report forms.